BioXcel Therapeutics (BTAI) PT Raised to $128 at Truist Securities
Truist Securities analyst Robyn Karnauskas raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $128.00 (from $127.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)